Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
Authors:
- John P. DiMarcoJohn P. DiMarco
- Gregory FlakerGFGregory Flaker
- Albert L. WaldoAWAlbert L. Waldo
- Scott D. CorleySCScott D. Corley
- H. Leon GreeneHGH. Leon Greene
- Robert E. SaffordRSRobert E. Safford
- Lynda E. RosenfeldLRLynda E. Rosenfeld
- Gladys MitraniGMGladys Mitrani
- Margit NemethMNMargit Nemeth
- 1 April 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 149 (4) , 650-656
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial InfarctionCirculation, 2002
- Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial FibrillationStroke, 2001
- Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial FibrillationCirculation, 2000
- Bleeding During Antithrombotic Therapy in Patients With Atrial FibrillationArchives of internal medicine (1960), 1996
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Stroke Prevention in Atrial Fibrillation Study. Final results.Circulation, 1991
- Canadian atrial fibrillation anticoaguiation (CAFA) studyJACC, 1991